Media Release SYDNEY, AUSTRALIA, July 28, 2023 Immutep Limited , a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today.
Immutep announces investigator-initiated Phase II trial evaluating LAG-3 candidate eftilagimod alpha (efti) in soft tissue sarcoma Expansion of the efti clinical development pipeline with a new Phase II settingEfti Phase II trial awarded EUR 1.5M (AUD 2.2M) in funding as part of the Polish Medical Research Agen.